ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $0.28 EPS, expectations were $0.32. ACADIA Pharmaceuticals Inc.

Related Keywords

United States ,Japan ,Toronto ,Ontario ,Canada ,United Kingdom ,American ,Japanese ,Mark Schneyer ,Parag Meswani ,Charles Duncan ,Tessa Romero ,Joel Beatty ,Al Kildani ,Steve Davis ,Doug Williamson ,David Hoang ,Brendan Teehan ,Gregory Renza ,Ashwani Verma ,Corporate Communications ,American Epilepsy Society ,Trial Court Level ,Pharmaceuticals Inc ,Pharmaceuticals Fourth Quarter ,European Medicines Agency ,Toronto Court Level ,Japanese Regulatory Agency ,Head Of Research ,Rett Centers Of Excellence ,Trial Court ,Morgan Stanley ,Acadia Pharmaceuticals Inc ,Nasdaq ,Rett Community ,Call Transcript February ,Fourth Quarter ,Full Year ,Results Conference ,Senior Vice President ,Investor Relations ,Chief Executive Officer ,Chief Operating Officer ,Chief Financial Officer ,Rare Disease Franchise ,Private Securities Litigation Reform Act ,Rett Centers ,Inflation Reduction ,Medicare Part D ,Easiest Languages ,English Speakers ,Wall Street ,Yash Verma ,Ritu Baral ,Jeff Hung ,Ami Fadia ,Markman Ruling ,